{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:16:16Z","timestamp":1781716576617,"version":"3.54.5"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,9,15]]},"DOI":"10.2169\/internalmedicine.2915-23","type":"journal-article","created":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T22:11:54Z","timestamp":1707689514000},"page":"2571-2578","source":"Crossref","is-referenced-by-count":6,"title":["Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib"],"prefix":"10.2169","volume":"63","author":[{"given":"Masami","family":"Yamazoe","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Hakodate Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hakodate Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Nagano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hakodate Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanami","family":"Nagano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hakodate Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hakodate Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hakodate Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hakodate Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Kamada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Aragu\u00e1s E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol 17: 816-828, 2018.","DOI":"10.1016\/S1474-4422(18)30254-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65: 25-34, 2011.","DOI":"10.1016\/j.jaad.2010.09.016"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 32: 3909-3915, 2012.","DOI":"10.1007\/s00296-011-2323-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23: 496-502, 2013.","DOI":"10.3109\/s10165-012-0663-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Motegi S, Sekiguchi A, Toki S, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 29: 511-517, 2019.","DOI":"10.1684\/ejd.2019.3634"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol 44: 319-325, 2017.","DOI":"10.3899\/jrheum.160682"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Romero-Bueno F, Diaz del Campo P, Trallero-Aragu\u00e1s E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50: 776-790, 2020.","DOI":"10.1016\/j.semarthrit.2020.03.007"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25: 925-933, 2016.","DOI":"10.1177\/0961203316651748"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72: 488-498, 2020.","DOI":"10.1002\/art.41105"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum 53: 151959, 2022.","DOI":"10.1016\/j.semarthrit.2022.151959"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46: 626-636, 2002.","DOI":"10.1067\/mjd.2002.120621"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features - a comprehensive review. Clin Rev Allergy Immunol 51: 293-302, 2016.","DOI":"10.1007\/s12016-015-8496-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Irie K, Matsumura N, Hoshi M, Yamamoto T. Inverse Gottron's papules in patients with dermatomyositis: an underrecognized but important sign for interstitial lung disease. Int J Dermatol 60: e62-e65, 2021.","DOI":"10.1111\/ijd.15204"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105: 1380-1387, 2011.","DOI":"10.1016\/j.rmed.2011.05.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Isoda K, Takeuchi T, Kotani T, et al. Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute\/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine A\/glucocorticosteroid combination therapy: a case control study. PLoS One 9: e89610, 2014.","DOI":"10.1371\/journal.pone.0089610"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fujiki Y, Kotani T, Isoda K, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol 28: 133-140, 2018.","DOI":"10.1080\/14397595.2017.1318468"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford) 57: 1212-1221, 2018.","DOI":"10.1093\/rheumatology\/key060"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51: 1563-1570, 2012.","DOI":"10.1093\/rheumatology\/kes102"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford) 59: 767-771, 2020.","DOI":"10.1093\/rheumatology\/kez357"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shirakashi M, Nakashima R, Tsuji H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford) 59: 3284-3292, 2020.","DOI":"10.1093\/rheumatology\/keaa123"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Saito T, Mizobuchi M, Miwa Y, et al. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series. J Clin Apher 36: 196-205, 2021.","DOI":"10.1002\/jca.21833"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takahashi R, Yoshida T, Morimoto K, et al. Successful treatment of anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive-interstitial lung disease by plasma exchange: two case reports. Clin Med Insights Case Rep 14: 11795476211036322, 2021.","DOI":"10.1177\/11795476211036322"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ibrahim RB, Balogun RA. Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. Semin Dial 25: 176-189, 2012.","DOI":"10.1111\/j.1525-139X.2011.01030.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 52: 1180-1196, 2008.","DOI":"10.1053\/j.ajkd.2008.02.360"},{"key":"25","unstructured":"25. Stigelman WH, Henry DH, Talbert RL, Townsend RJ. Removal of prednisone and prednisolone by plasma exchange. Clin Pharm 3: 402-407, 1984."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Szefler SJ, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol 30: 323-329, 1986.","DOI":"10.1007\/BF00541537"},{"key":"27","unstructured":"27. Przepiorka D, Suzuki J, Ippoliti C, Hester JP, Fritsche HA. Blood tacrolimus concentration unchanged by plasmapheresis. Am J Hosp Pharm 1: 1708, 1994."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Jacobson P, Uberti J, Davis W, Ratanatharathorn V. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 22: 217-225, 1998.","DOI":"10.1038\/sj.bmt.1701331"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Juma FD, Rogers HJ, Trounce JR. The kinetics of salivary elimination of cyclophosphamide in man. Br J Clin Pharmacol 8: 455-458, 1979.","DOI":"10.1111\/j.1365-2125.1979.tb01025.x"},{"key":"30","unstructured":"30. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34: 318-328, 2016."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381: 291-293, 2019.","DOI":"10.1056\/NEJMc1900045"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57: 2114-2119, 2018.","DOI":"10.1093\/rheumatology\/key188"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hosokawa Y, Oiwa H. A case of refractory interstitial lung disease in anti-MDA5-positive dermatomyositis that improved after switching to tofacitinib. J Clin Rheumatol 27: S661-S662, 2021.","DOI":"10.1097\/RHU.0000000000001645"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Suzuka T, Kotani T, Takeuchi T, et al. Efficacy and safety of oral high-trough level tacrolimus in acute\/subacute interstitial pneumonia with dermatomyositis. Int J Rheum Dis 22: 303-313, 2019.","DOI":"10.1111\/1756-185X.13414"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Ida T, Furuta S, Takayama A, et al. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open 9: e002795, 2023.","DOI":"10.1136\/rmdopen-2022-002795"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/18\/63_2915-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T03:28:49Z","timestamp":1726889329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/18\/63_2915-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,15]]},"references-count":35,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2915-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,15]]},"article-number":"2915-23"}}